|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Institute on Drug Abuse (NIDA) |
|---|---|
| Collaborator: |
New York State Psychiatric Institute |
| Information provided by: | National Institute on Drug Abuse (NIDA) |
| ClinicalTrials.gov Identifier: | NCT00000273 |
Purpose
The purpose of this study is to evaluate the effects of treatment medications (methadone, buprenorphine, LAAM, naltrexone, naltrexone microcapsules, and methoclocinnamox) on I.V. and smoked heroin self-administration."
| Condition | Intervention | Phase |
|---|---|---|
|
Heroin Dependence Opioid-Related Disorders Substance-Related Disorders |
Drug: opiates |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Outcomes Assessor), Placebo Control, Crossover Assignment, Pharmacodynamics Study |
| Official Title: | A Laboratory Model for Heroin Abuse Medications |
| Estimated Enrollment: | 37 |
| Study Start Date: | August 1995 |
| Estimated Study Completion Date: | December 2009 |
| Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Opiate abuser: Experimental |
Drug: opiates
prescription opioids
|
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Please contact site for information.
Contacts and Locations| Contact: Sandra D Comer, Ph.D. | 212-543-5981 | sdc10@columbia.edu |
| Contact: Phillip Saccone, BS | 212-543-5319 | saccone@pi.cpmc.columbia.edu |
| United States, New York | |
| Columbia University | Recruiting |
| New York, New York, United States, 10032 | |
| Contact: Sandra D Comer, Ph.D. 212-543-5981 sdc10@columbia.edu | |
| Contact: Phillip Saccone, BS 212-543-6243 saccone@pi.cpmc.columbia.edu | |
| Principal Investigator: | Herbert Kleber, M.D. | New York State Psychiatric Institute |
More Information
| Responsible Party: | Columbia University and the New York State Psychiatric Institute ( Sandra D. Comer, PhD ) |
| Study ID Numbers: | NIDA-09236-8, P50 DA009236-08 |
| Study First Received: | September 20, 1999 |
| Last Updated: | July 8, 2009 |
| ClinicalTrials.gov Identifier: | NCT00000273 History of Changes |
| Health Authority: | United States: Federal Government; United States: Institutional Review Board; United States: Food and Drug Administration |
|
Pathologic Processes Disease Mental Disorders Heroin Dependence |
Substance-Related Disorders Disorders of Environmental Origin Opioid-Related Disorders |